Dendritic Polymer Nanoparticles for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
PEGylated drugs often induce anti-PEG antibodies, leading to accelerated blood clearance, reduced efficacy, and potentially life-threatening side effects due to enhanced accumulation in the liver and spleen.
Innovation Solution
Development of nanoparticle compositions comprising a dendritic-polymer skeleton with a PEG moiety, an amine, and a hydrophobic unit, where the PEG moiety is limited in size to minimize immune recognition, and includes additional components like lipid conjugates and cholesterol to enhance delivery and reduce immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If PEGylated carriers are used for drug delivery, then circulatory half-life and biocompatibility are improved, but anti-PEG antibodies are induced leading to accelerated blood clearance and reduced efficacy
Solution Approach 1:
The patent changes the molecular weight parameter of PEG from conventional high values (2000-5000 Da) to low values (200-500 Da), and alters the structural parameter by using dendritic architecture instead of linear chains. These parameter changes maintain the circulatory half-life benefit while reducing immunogenicity and anti-PEG antibody induction, thereby resolving the contradiction between prolonged circulation and maintained efficacy
Solution Approach 2:
The patent creates a composite carrier structure combining dendritic polymer backbone with PEG side chains, rather than using conventional linear PEGylated structures. This composite approach integrates the structural benefits of dendrimers (high functional group density, controlled architecture) with the biocompatibility of PEG, achieving both prolonged circulation and reduced immune recognition
2Productivity
If PEGylated drugs are administered repeatedly, then initial therapeutic effect is achieved, but anti-PEG antibodies accumulate causing accelerated blood clearance and hypersensitivity
Solution Approach 1:
By changing the PEG molecular weight parameter to low values (200-500 Da) and using dendritic architecture, the patent reduces the immunogenicity of the carrier. This allows repeated administrations to maintain therapeutic effect without accumulating anti-PEG antibodies, preventing hypersensitivity and accelerated blood clearance
Solution Approach 2:
The patent uses short PEG chains (200-500 Da) that are less immunogenic and can be cleared more efficiently, replacing the conventional long PEG chains. These shorter PEG moieties act as temporary protective coatings that do not persist long enough to induce strong immune responses, enabling safe repeated dosing
3Quantity of substance
If PEG-conjugates accumulate in liver and spleen, then initial delivery is achieved, but enhanced accumulation leads to potentially life-threatening side effects
Solution Approach 1:
The patent changes the size parameter of PEG from large conjugates to small moieties (200-500 Da), and modifies the structural parameter through dendritic architecture. These changes reduce the overall size and hydrophobicity of the PEG-conjugate complex, decreasing nonspecific accumulation in reticuloendothelial system organs like liver and spleen, thereby reducing toxicity while maintaining delivery efficacy
Data Source
AI summary
The present disclosure relates to nanoparticle compositions for delivery of nucleic acid agents. The nanoparticle composition disclosed includes a carrier containing a dendritic polymer skeleton, a PEG moiety, an amine, and a hydrophobic unit. The size of the PEG moiety may be limited, potentially reducing or avoiding anti-PEG antibody induction.